generic speaker image
Adrian Newman-Tancredi - NeuroAct Communication. Castres, Tarn, FR

Adrian Newman-Tancredi Adrian Newman-Tancredi

Neuropharmacology Consulting | NeuroAct Communication

Castres, Tarn, FRANCE

Experienced public speaker and neuropharmacologist with proven expertise in study of antipsychotics, antidepressants and analgesics.

Social

Biography

Dr. Newman-Tancredi has over 20 years' experience of neuroscience research and drug discovery. Prior to joining Neurolixis, he was Director of Neurobiology and Project Manager at Pierre Fabre Laboratories where he led multi-disciplinary programs that successfully identified and characterized novel antipsychotics, antidepressants and analgesics. Prior to Pierre Fabre, Dr. Newman-Tancredi led a molecular pharmacology research group at the Servier Research Institute where he was responsible for screening of NCEs and investigating signal transduction mechanisms of monoamine receptors. Drugs characterized in the course of Dr. Newman-Tancredi's work include milnacipran (Savella ®), piribedil (Trivastal ®), agomelatine (Valdoxan ®) and befiradol (Ph. II). In addition, Dr. Newman-Tancredi managed projects that led to early development of compounds with novel profiles of action, including the antipsychotic candidate, F15063 and the antidepressant candidate, F15599.

Dr. Newman-Tancredi has extensive experience of team management, integrating medicinal chemistry, pharmacology, early ADMET and preclinical development, and building international collaborations with academic researchers. He has published over 130 research reports, co-authored patents on NCEs and given presentations to a wide variety of audiences. He serves on the Editorial Board of the International Journal of Neuropsychopharmacology and as an independent neuropharmacology and drug discovery consultant (www.neuroact.com). Dr. Newman-Tancredi received his B.Sc. with honours in Biochemistry and his Ph.D. in neuropharmacology from the University of Kent at Canterbury, U.K. He is bi-national (anglo-italian) and tri-lingual (English, French, Italian).

Industry Expertise (3)

Pharmaceuticals Research Mental Health Care

Areas of Expertise (4)

Antipsychotics Neuropharmacology Serotonin Depression

Education (3)

University of Kent at Canterbury: BSc, Biochemistry 1988

University of Kent at Canterbury: PhD, Neuropharmacology 1992

University of Kent at Canterbury: DSc, Neuropharmacology 2013

Affiliations (2)

  • NeuroAct Communication
  • Neurolixis Inc.

Event Appearances (7)

The development of a novel generation of antipsychotics combining 5-HT1A agonism and D2 antagonism: rationale and new perspectives

9th International Meeting on the Early Phases of Mental Disorders  Santander, Spain

2011-10-20

Antipsychotics in the post-patent cliff era: challenges for clinical and drug discovery research.

24th European College of Neuropsychopharmacology (ECNP) Congress  Paris, France

2011-09-05

New mechanisms and novel drugs: how recent discoveries are opening perspectives for targeting serotonergic neurotransmission

Invited lecture: CERMEP Brain Imaging Centre  Boulevard Pinel Hospital, Lyon, France

2011-03-13

Pharmaceutical drug discovery - challenges and opportunities

Invited lecture: Neuropsychopharmacology Masters Degree students  Bordeaux II University, Bordeaux, France

2011-11-16

Searching for an optimised pharmacological cocktail: focus on antipsychotics with combined D2 and serotonin 5-HT1A activity.

23rd European College of Neuropsychopharmacology (ECNP) Congress  Amsterdam, Netherlands

2010-08-25

De la schizophrénie aux troubles de l'humeur: une brève histoire des antipsychotiques

10th Encéphale Congress of French Psychiatry  Palais des Congrès, Paris, France

2012-01-18

Psychopharmacology of monoamines

Association Française de Psychiatrie Biologique et de la Neuropsychopharmacologie (AFPBN)  Palais Brongniart, Paris, France

2012-03-15

Sample Talks (1)

Searching for an optimised pharmacological cocktail: focus on antipsychotics with combined D2 and serotonin 5-HT1A activity.

This lecture presented the importance of serotonin 5-HT1A receptors as targets for the development of improved antipsychotics for the treatmenf of schizophrenia and related CNS disorders. The lecture focused on evidence from rodent models of psychosis, social withdrawal and cognitive deficits. Watch the Webcast of this lecture on YouTube: http://www.youtube.com/watch?v=vDc6QbwxUO8

Style

Availability

  • Keynote
  • Moderator
  • Panelist
  • Workshop Leader
  • Host/MC

Fees

1000 to 5000 *Will consider certain engagements for no fee
Contact